GLP-1 clinical trials in Alabama: 16 recruiting now

16 GLP-1 clinical trials are recruiting at 18 sites in 7 cities across Alabama. Every site below is listed with its city and, where the sponsor publishes one, the number to call.

Every study recruiting in Alabama

1. PREvention of CardIovascular and DiabEtic kidNey Disease in Type 2 Diabetes

   Phase 4. Run by Brigham and Women's Hospital. Registry number NCT05390892.

   A study testing whether a GLP-1 medicine, semaglutide, can help people lower blood sugar.

   Who can join. Adults 40 to 80, have type 2 diabetes.

   1 site in Alabama

   • Longwood Research LLC, Huntsville. 256-489-2879

2. A Study of Orforglipron in Female Participants With Stress Urinary Incontinence Who Have Obesity or Overweight

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07202884.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people reduce bladder leaks.

   Who can join. Adults 18+, women only, have stress urinary incontinence (bladder leaks), BMI 27+.

   2 sites in Alabama

   • University of Alabama -The Kirklin Clinic, Birmingham
   • AMR Clinical, Mobile

3. A Clinical Study to Compare Efficacy and Safety of Two Different Doses of CagriSema and Semaglutide in Participants With Obesity

   Phase 3. Run by Novo Nordisk A/S. Registry number NCT07564414.

   A study testing whether a study medicine from Novo Nordisk, cagrisema, can help people with type 2 diabetes lose weight.

   Who can join. Adults 18+, have obesity, BMI 35+.

   2 sites in Alabama

   • Uni of Alabama at Birmingham, Birmingham
   • Cahaba Research, Pelham

4. LIVERAGE™: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Moderate or Advanced

   Phase 3. Run by Boehringer Ingelheim. Registry number NCT06632444.

   A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (also called MASH or NASH) with liver scarring (fibrosis).

   1 site in Alabama

   • University of Alabama at Birmingham, Birmingham. 833-602-2368

5. Mirikizumab Administered at the Same Time as Tirzepatide in Adult Participants With Moderately to Severely Active Ulcerative

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06937086.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with ulcerative colitis calm gut inflammation.

   Who can join. Adults 18 to 70, have ulcerative colitis, BMI 27+.

   1 site in Alabama

   • Digestive Health Specialists, Dothan. 334-836-1212

6. Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn's Disease and Obesity

   Phase 3. Run by Eli Lilly and Company. Registry number NCT06937099.

   A study testing whether a GLP-1 and GIP medicine from Lilly, tirzepatide, can help people with Crohn's disease calm gut inflammation.

   Who can join. Adults 18 to 70, have Crohn's disease, BMI 27+.

   1 site in Alabama

   • Digestive Health Specialists, Dothan. 334-836-1212

7. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07165028.

   A study testing whether a GLP-1, GIP and glucagon medicine from Lilly, retatrutide, can help people reduce liver fat.

   Who can join. Adults 18+, have fatty liver disease (MASLD), BMI 25+.

   1 site in Alabama

   • MFA Clinical Research, Tuscaloosa. 205-331-4963

8. Efficacy and Safety of Orforglipron in Participants With Peripheral Artery Disease

   Phase 3. Run by Eli Lilly and Company. Registry number NCT07223593.

   A study testing whether a GLP-1 medicine from Lilly, orforglipron, can help people improve blood flow in the legs.

   Who can join. Adults 18+, have peripheral artery disease (poor blood flow in the legs), BMI 23+.

   1 site in Alabama

   • St. Vincent's Birmingham Hospital, Birmingham

9. A Phase 3, Open-label Trial to Evaluate the Efficacy, Safety and Tolerability of Switching From the Glucagon-like Peptide-1

   Phase 3. Run by Amgen. Registry number NCT07575399.

   A study testing whether a study medicine from Amgen, Maridebart Cafraglutide, can help people lose weight.

   Who can join. Adults 18+, have obesity or are overweight, BMI 25+.

   1 site in Alabama

   • Cahaba Research, Inc., Pelham

10. A Randomized, Open-label, Parallel-group Phase III Study to Evaluate the Efficacy, Safety, and Tolerability of Elecoglipron

    Phase 3. Run by AstraZeneca. Registry number NCT07662213.

    A study testing whether a GLP-1 medicine, semaglutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Alabama

    • Research Site, Birmingham

11. A Study to Test Whether Survodutide Helps People With Type 2 Diabetes Control Their Blood Sugar

    Phase 3. Run by Boehringer Ingelheim. Registry number NCT07754461.

    A study testing whether a GLP-1 and glucagon medicine from Boehringer Ingelheim, survodutide, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18+, have type 2 diabetes, BMI 23+.

    1 site in Alabama

    • Cahaba Research, Inc. - Trussville Location, Birmingham. 833-602-2368

12. Research Study on How Well Oral Semaglutide Works for Weight Loss in Adults With Excess Body Weight

    Phase 3. Run by Novo Nordisk A/S. Registry number NCT07770841.

    A study testing whether a GLP-1 medicine from Novo Nordisk, semaglutide, can help people lose weight.

    Who can join. Adults 18+, are overweight, BMI 27+.

    1 site in Alabama

    • Uni of Alabama at Birmingham, Birmingham

13. NAUTICAL: Effect of Natriuretic Peptide Augmentation on Cardiometabolic Health in Black Individuals

    Phase 2. Run by University of Alabama at Birmingham. Registry number NCT04055428.

    A study of sacubitril/valsartan (97/103 mg oral tablet).

    1 site in Alabama

    • University of Alabama at Birmingham, Birmingham. 205-934-7173

14. Phase 2 Randomized, Double-blind, Placebo-Controlled Trial Assessing the Efficacy and Safety of Icovamenib in Participants

    Phase 2. Run by Biomea Fusion Inc. Registry number NCT07502508.

    A study testing whether an investigational medicine from Biomea Fusion, icovamenib, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 70, have type 2 diabetes, BMI 25+.

    1 site in Alabama

    • Central Research Associates, LLC dba Flourish Research, Birmingham

15. A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07639021.

    A study testing whether an investigational medicine from Novo Nordisk, NNC0662-0419, can help people lose weight.

    Who can join. Adults 18+, have obesity, BMI 30+.

    1 site in Alabama

    • Chambliss Clinical Trials, LLC, Montgomery

16. A Research Study Comparing How Well Different Doses of the Medicine UBT251 Lower Blood Sugar in People With Type 2 Diabetes

    Phase 2. Run by Novo Nordisk A/S. Registry number NCT07668388.

    A study testing whether an investigational medicine from Novo Nordisk, UBT251, can help people with type 2 diabetes lower blood sugar.

    Who can join. Adults 18 to 75, have type 2 diabetes.

    1 site in Alabama

    • Flourish Research, Birmingham

Source: ClinicalTrials.gov, the federal registry, read September 4, 2026. Open a study's registry record before you call: it can close to new participants at any time. GLP Chart does not enroll anyone, is not paid for clinical-trial referrals and has no relationship with any sponsor or site on this page.

John Samaras, Founder and EditorI started GLP Chart after overpaying for a GLP-1 myself. Based in Austin, Texas.
About this siteLinkedInContact